the american lab Johnson & Johnson entry $2,385 million in the whole of 2021 exclusively from sales of its vaccine against COVID-19, As reported by the company on Tuesday when presenting its annual accounts.
Of that accumulated billing figure between January and December, sales in the United States were $634 million, while in the rest of the world they amounted to $1,751 million.
In the fourth quarter of last year alone, sales of the vaccine by Janssen, a subsidiary of Johnson & Johnson, reached $1,619 million.
The vast majority, $1,405 million, came from abroad, while the remaining $213 million was due to sales to the United States.
Although the sales data is bulky for a single product, they only represented a small fraction of the company’s total revenue.
Thus, for the year as a whole, Johnson & Johnson’s turnover was $93,775 million, 13.6% more than in 2020.
By business segments, the pharmacy division grew by 14.3%, to $52,080 million, while sales of medical devices grew by 17.9%, to $27,060 million.
The branch of consumer products increased by 4.1%, standing at $14,635 million.
Cost of goods sold was $29,885 million, up 5%, while selling, marketing and administrative expenses rose 11.7% to $24,659 million.
The research and development (R&D) item expanded by 21%, to $14,714 million.
In this way, the multinational’s net profit in 2021 was $20,878 million, 41.9% more than in the previous year.
Only in reference to the fourth quarter of 2021, Johnson & Johnson’s net profit was $4,736 million, which is equivalent to multiplying the profit of the same quarter of 2020 by 2.7. On the other hand, sales grew by 10.4% , up to $24,804 million.